A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

June 25, 2018

Study Completion Date

June 25, 2018

Conditions
Restless Legs Syndrome (RLS)
Interventions
DRUG

Placebo

Oral administration

DRUG

Gabapentin enacarbil

Oral administration

Trial Locations (46)

Unknown

Site JP00025, Nagoya

Site JP00029, Nagoya

Site JP00040, Nagoya

Site JP00006, Kitakyushu

Site JP00022, Kitakyushu

Site JP00002, Sapporo

Site JP00003, Sapporo

Site JP00004, Sapporo

Site JP00023, Sapporo

Site JP00041, Kawanishi

Site JP00005, Kobe

Site JP00038, Kawasaki

Site JP00007, Yokohama

Site JP00017, Yokohama

Site JP00049, Yokohama

Site JP00050, Yokohama

Site JP00009, Yokosuka

Site JP00032, Sakai

Site JP00043, Tokorozawa

Site JP00012, Arakawa City

Site JP00001, Chōfu

Site JP00028, Chōfu

Site JP00018, Chūō

Site JP00024, Chūō

Site JP00048, Meguro City

Site JP00034, Musashino

Site JP00046, Nakano City

Site JP00019, Ōta-ku

Site JP00011, Shibuya City

Site JP00013, Shinagawa

Site JP00015, Shinagawa

Site JP00016, Shinagawa

Site JP00008, Shinjuku

Site JP00014, Shinjuku

Site JP00021, Shinjuku

Site JP00031, Chiba

Site JP00036, Fukuoka

Site JP00020, Kyoto

Site JP00035, Kyoto

Site JP00010, Osaka

Site JP00026, Osaka

Site JP00037, Osaka

Site JP00039, Osaka

Site JP00047, Osaka

Site JP00030, Saitama

Site JP00044, Saitama

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY